Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis

Cheng Yuan Xue1,2†, Meng Qi Zhou1,2†, Qi Yan Zheng3, Jin Hui Zhang1, Wei Ting Cheng1,2, Xue Hui Bai1,2, Fen Zhou4, Ai Ming Wu1,2, Bo Nie1,2, Wei Jing Liu1,2* and Li Xia Lou1,2*

1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, 2Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Beijing, China, 3Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China, 4Nursing School, Beijing University of Chinese Medicine, Beijing, China

Rosiglitazone (Avandia) and pioglitazone (Actos) belong to the class of thiazolidinediones (TZDs) drugs that act by increasing insulin sensitivity and are widely used for treating diabetic patients with insulin resistance. TZDs exhibit anti-inflammatory and antioxidant properties, then may play an active role in inhibiting plaque formation and coronary atherosclerosis. But the results of evidence-based medicine suggest that TZDs may increase the risk of cardiovascular adverse events. To explore the dispute in depth, our meta-analysis aimed to evaluate the changes in vascular endothelial and plaque-related indicators following treatment with TZDs in diabetic patients with coronary atherosclerosis. According to our meta-analysis, TZDs showed an inhibiting effect on plaque progression and a protective effect on the vascular endothelium in patients with diabetes and coronary atherosclerosis. Interestingly, these effects may not depend on the regulation of inflammation and lipid metabolism. By this token, TZDs may develop a potential protective effect on myocardial infarction.

Systematic review registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021231663].

KEYWORDS
thiazolidinediones (TZDs), rosiglitazone, pioglitazone, endothelium, plaque, diabetes, coronary atherosclerosis
Introduction

Globally, 537 million adults (20–79 years) are living with diabetes. This number is predicted to rise to 643 million by 2030 and 784 million by 2045 (1). Diabetes has been considered to be associated with an increased risk of cardiovascular disease (2). Many studies have shown that people with diabetes are 2-4 times more likely than the general population to develop cardiovascular disease and have an increased mortality risk (3). There is an increasing number of patients who suffer from diabetes concomitant with cardiovascular disease. In general, simple diabetes and diabetes combined with cardiovascular disease have different treatment purposes and specific principles. Finding a drug with both hypoglycemic action and cardiovascular protecting effects is very necessary.

Rosiglitazone and pioglitazone belong to the class of thiazolidinediones (TZDs) that act by increasing insulin sensitivity and are widely used for treating patients with type 2 diabetes mellitus (T2DM). TZDs have been reported to have both anti-inflammatory and antioxidant functions, which are thought to be the major causes of coronary atherosclerosis (4). Accordingly, TZDs are believed to have a role in preventing coronary atherosclerotic heart disease. But currently, there has been controversy over TZDs in the cardiovascular field. A meta-analysis in May 2007 reported for the first time that rosiglitazone increased the risk of myocardial infarction by 43%, which showed that TZDs may have cardiovascular adverse effects (5). Subsequently, a series of evidence-based medical evidence was published that the increased risk of heart failure due to TZDs is relatively clear, but researchers failed to reach consistent conclusions on the myocardial infarction risk of TZDs. Recently, a meta-analysis with a sample size of 21156 summarized the effects of rosiglitazone on cardiovascular risk and mortality (6). The results suggested that rosiglitazone was associated with an increased cardiovascular risk, especially for heart failure events, the odds ratios for myocardial infarction were 1.17. But the authors were cautious about the result, because of the small confidence intervals and large diversity between different analysis methods. An umbrella review concludes: the risk ratios for heart failure between the pioglitazone intervention group and the control group were 1.40, which suggests a 40% increase in myocardial infarction risk after pioglitazone intervention (7). However, pioglitazone is well-known before to have a protective effect on cardiovascular disease including heart failure events in patients with diabetes (8). Hence, the relationship between TZDs and cardiovascular risk was still unclarified.

Endothelium, whose dysfunction is implicated in several pathophysiologic processes, including atheromatous plaque formation and coronary artery pathological changes, is considered to be an important target for TZDs in coronary atherosclerosis (9). The analysis and judgment of the effects of TZDs on endothelial-related indicators or atheromatous plaques will be of great help to our understanding of the association between TZDs and cardiovascular diseases, especially myocardial infarction. Our meta-analysis was designed to assess changes in vascular endothelial and plaque-related indices after rosiglitazone or pioglitazone treatment in patients with diabetes combined with coronary atherosclerosis, and to explore potential targets for the protective effects of TZDs in myocardial infarction.

Materials and methods

This meta-analysis was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline (PRISMA) (10), with our protocol registered in PROPERO as CRD42021231663.

Literature search strategy

To find relevant peer-reviewed studies regarding TZDs and endothelium in diabetic patients with coronary atherosclerosis, different electronic databases including PubMed/Medline, EMBASE, Web of Science, and Cochrane Library were used. The search terms included “Coronary Artery Disease,” “Endothelium,” “TZDs,” “Glitazones,” “Rosiglitazone,” etc. The combinations of different search terms were used for identifying the relevant articles, and the search strategies were customized to suit each database (see Supplementary Table 1).

Criteria for inclusion and exclusion

Inclusion criteria for this study were the following: (a) the study must be a randomized controlled trial design; (b) it should be published in a peer-reviewed journal in the English language; (c) studies should have clear diagnostic criteria about diabetic patients with coronary atherosclerosis; (type 2 diabetes mellitus according to the diagnostic criteria of T2DM published in the American Diabetes Association, and coronary heart disease or vascular stent surgery suggesting coronary atherosclerosis) (d) reported studies should be available in full text (not editorial, commentary, or abstract for conferences). Studies were excluded if (a) they were published in other languages than English and contained only qualitative data; (b) the intervention and control groups mixed up patients with other diseases; (c) the combination application of TZDs was present in the intervention group.

Data extraction and management

Two authors (Cheng Yuan Xue and Meng Qi Zhou) reviewed the titles, abstracts, and/or full texts for each of the
articles identified by the literature search after the removal of duplicates, aiming to determine the eligibility for this meta-analysis. During the study selection process, discrepancies were resolved by discussion with a third author (Qi Yan Zheng). All authors independently performed data extraction using standard extraction spreadsheets from the selected articles based on the inclusion criteria and enlisted them in a table. The following items were extracted from each study: author’s name (first author), year of publication, country, groups, gender distribution, mean age (years), several participants (male vs. female), vessel volume, lumen volume, plaque volume, neointima volume, flow-mediated dilatation, adiponectin, endothelin, NO, NOS, CRP, interleukin-6, TNF-α, triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol. After the extraction of the data, the authors cross-checked the data tables and resolved any conflicts and inconsistencies during the data extraction process through discussion with each other.

Quality assessment

The quality assessment of all included studies was conducted by using the Cochrane Collaboration “Risk of Bias” tool (11). We expand our analysis through the following six items: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases. Each entry was also classified into three levels of bias risk: “high risk,” “low risk” and “uncertain risk”. The two evaluators evaluated the literature quality, respectively, and the differences were determined by a third party.

Published bias

The number of studies on the same outcome measure was too small, so publication bias was tested without funnel plots.

Statistical analysis

We used the statistical software named Review Manager V5.4.1 (Cochrane Collaboration, Copenhagen, Denmark) for the meta-analysis. Most of the results were analyzed using the fixed-effects model and forest plots. For strong heterogeneous results, we used the random-effect model as the statistical method, which seems to provide more conservative results than the fixed-effects model (12).

We calculated the standardized mean difference (SMD) with a corresponding 95% confidence interval (CI) for each parameter using the random-effects model. A P-value < 0.05 was considered a statistically significant difference between groups. The existence of heterogeneity among studies was evaluated using I² and its resultant P-value using chi-squared tests. I² values of 0–25%, 25–50%, 50–75% and above 75% correspondence to the heterogeneity as absence or very low, low, medium, and high, respectively, if the P-value was smaller than 0.1, the results were considered to be heterogeneous.

Results

Search results

As shown in Figure 1, a total of 117 studies were initially identified through different database searching. After the removal of duplication, additional screening, and analysis of the titles, abstracts, or full texts for each of the articles, 28 articles were included as eligible for this study. For articles where the full text is available, we read the full text carefully, 20 articles were excluded because they are not RCT, single-handed intervention or we can’t find the full text. Finally, 8 studies were included in the qualitative and quantitative review and meta-analysis of our study.

Characteristics of included studies

The main characteristics of participants and interventions are presented in Table 1. There were 451 participants enrolled in the 8 studies.

Our meta-analysis suggested that at baseline levels, there was no statistically significant difference between the intervention and control groups (all P > 0.05; Table 2).

Risk of bias

All eight randomized controlled trials mentioned randomization and blindness methods. We evaluated the credibility of the information provided by the articles: 1 grouped by the randomized digital table; 1 literature mentioned single blindness, with the possibility of breaking blindness; the rest 6 mentioned blindness to researchers, subjects, and data analysts; insufficient data in the literature to indicate follow-up bias and reporting bias, no missing data and pre-reported outcomes have been reported. The results are shown in Figure 2.

Thiazolidinediones delayed plaque progression

We included three or four studies in the meta-analysis to evaluate the effect of TZDs on the plaque. As shown in
Figure 3A, the values of plaque volume are the result of the subtraction of vessel volume and lumen volume. The data from three of the four publications are complete and the other one "Olivier 2020" records only the result of the subtraction (Figure 3D).

We found a low level of heterogeneity for vessel volume among the existing studies ($I^2 = 0\%$, $P = 0.71$) (Figure 3B). Based on the fixed-effects model of meta-analysis, lower levels of vessel volume were observed in the intervention group compared to the control subjects (SMD [95% CI]: $-0.33$ [−0.63, −0.04], $Z = 2.23$, $P = 0.03$). Then we found a medium level of heterogeneity for lumen volume among the existing studies ($I^2 = 60\%$, $P = 0.08$) (Figure 3C). Based on the random-effects model of meta-analysis the difference between the intervention group and the control group was not statistically significant (SMD [95% CI]: 0.01 [−0.47, 0.50], $Z = 0.04$, $P = 0.97$). Heterogeneity mainly stems from the study "C. M. Ahn 2010", which reported that the vessel volume decreased, the lumen volume increased, and the plaque volume decreased in the intervention group, and the final results were still in line with the overall trend. Finally, a very low level of heterogeneity for plaque volume was found among the existing studies ($I^2 = 0\%$, $P = 0.74$) (Figure 3D). Based on the fixed-effects model of meta-analysis, significantly lower levels of plaque volume were observed in the intervention group compared to the control subjects (SMD [95% CI]: −0.46 [−0.67, −0.24], $Z = 4.18$, $P < 0.0001$).
Thiazolidinediones increased the adiponectin but didn’t affect the C reactive protein and interleukin-6 significantly

There were two to four studies to be included in the meta-analysis to evaluate the overall effect of TZDs on adiponectin, CRP, and IL-6. These indicators are thought to be closely related to inflammation. We found a high level of heterogeneity for adiponectin among the existing studies ($I^2 = 93\%$, $P < 0.00001$) (Figure 4A). Based on the random-effects model of meta-analysis, significantly higher levels of adiponectin were observed in the intervention group compared to the control subjects. (SMD [95% CI]: 1.36[0.10, 2.61], $Z = 2.12$, $P = 0.03$). A high
TZDs slowed the progression of plaque attachment on the vascular endothelium. (A) The relationship above vessel volume, lumen volume, and plaque volume; the materials in the figure were provided by Servier Medical Art (https://smart.servier.com) under a CC BY 3.0 license. (B) Effect of the TZDs on the vessel volume (mm$^3$/mm). (C) Effect of the TZDs on the lumen volume (mm$^3$/mm). (D) Effect of the TZDs on the plaque volume (mm$^3$/mm).

TZDs increased adiponectin but didn’t affect CRP and IL-6 significantly. (A) Effect of the TZDs on the adiponectin. (B) Effect of the TZDs on the CRP (mg/L). (C) Effect of the TZDs on the IL-6 (ng/L).

Level of heterogeneity for CRP also appeared among the existing studies ($I^2 = 94\%$, $P < 0.00001$) (Figure 4B). Based on the random-effects model of meta-analysis, the difference was not statistically significant (SMD [95% CI]: $-0.75[-1.90, 0.40]$, $Z = 1.27$, $P = 0.20$). Finally, only two studies were included in the meta-analysis to evaluate the overall effect of TZDs on IL-6. We found a high level of heterogeneity for IL-6 among the existing studies ($I^2 = 94\%$, $P < 0.00001$) (Figure 4C). Based on
FIGURE 5
The effect of the TZDs on the serum lipid profile was unstable. (A) Effect of the TZDs on TG (mmol/L). (B) Effect of the TZDs on TC (mmol/L). (C) Effect of the TZDs on LDL-C (mmol/L). (D) Effect of the TZDs on HDL-C (mmol/L).

The random-effects model of meta-analysis, the difference was not statistically significant (SMD [95% CI]: −0.80 [−2.63, 1.04], Z = 0.85, P = 0.39).

Thiazolidinediones did not affect the serum levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol

There were five studies to be included in the meta-analysis to evaluate the overall effect of TZDs on TG. We found a medium level of heterogeneity for TG among the existing studies (I² = 63%, P = 0.03) (Figure 5A). Based on the random-effects model of meta-analysis, the difference was not statistically significant (SMD [95% CI]: 0.25 [−0.15, 0.65], Z = 1.23, P = 0.22). For sensitivity analysis, the group heterogeneity was reduced by excluding the study “HARALD SOURIRI 2006” (P = 0.48, I² = 0%), higher levels of triglyceride were found in the intervention group compared to the control subjects in the fixed-effect model meta-analysis, but the difference was not statistically significant (SMD [95% CI]: 0.10[−0.15, 0.35], Z = 0.76, P = 0.44). Analogously, there were five studies to be included in the meta-analysis to evaluate the effect of TZDs on TC. We found a high level of heterogeneity for TC among the existing studies (I² = 85%, P < 0.0001) (Figure 5B). Based on the random-effects model of meta-analysis, the difference was not statistically significant (SMD [95% CI]: 0.49 [−0.23, 0.14], P = 0.62). For sensitivity analysis, the group heterogeneity was reduced by excluding the study “J YU 2010”, (P = 0.98, I² = 0%), and the fixed-effect model meta-analysis
revealed that the intervention group’s total cholesterol levels were greater than those of the control subjects. (SMD [95% CI]: 0.27 [0.06, 0.48], Z = 2.51, P = 0.01) In summary, the level of TC after the intervention of TZDs was unstable.

Six studies were included in the meta-analysis to evaluate the effect of TZDs on LDL-C. We found a very low level of heterogeneity for LDL-C among the existing studies (I² = 0%, P = 0.44) (Figure 5C). Based on the fixed-effects model of meta-analysis, the difference was not statistically significant. (SMD [95% CI]: −0.05 [−0.23, 0.14], Z = 0.49, P = 0.62). Finally, there were six studies to be included in the meta-analysis to evaluate the overall effect of TZDs on HDL-C. We found a low level of heterogeneity for HDL-C among the existing studies (I² = 23%, P = 0.26) (Figure 5D). Based on the fixed-effects model of meta-analysis, the difference was not statistically significant (SMD [95% CI]: 0.15 [−0.04, 0.33], Z = 1.57, P = 0.12).

Discussion

According to previous reports, among the various types of medicine used in diabetes patients, TZDs were explored to have an inhibitory effect on cardiovascular disease by regulating serum lipid levels, serum adiponectin levels, and inflammatory response (21, 22). Research has shown that pioglitazone can reduce a range of cardiovascular risk factors, such as lipid unbalance, endothelial dysfunction, and inflammatory response (23). Furthermore, a randomized controlled trial with a large sample confirmed that TZDs have an anti-atherosclerotic effect (24). But there are still different opinions and controversies regarding the association between TZDs and the myocardial infarction to date. To demonstrate the role of TZDs in the treatment of diabetes combined with atherosclerosis, we performed this meta-analysis to explore the effect of TZDs on the plaque, vascular endothelium, and other indicators related to coronary atherosclerosis.

Based on our meta-analysis, in diabetic patients with coronary atherosclerosis, TZDs treatment resulted in an overall improvement in adiponectin and an inhibition of plaque volume. The results indicated that TZDs could protect the endothelium and reduce plaques. An essential function of the endothelium is to respond to physiological stimuli and produce transient vasodilators, including nitric oxide, bradykinin, and prostacyclin. The hyperglycemic state activates the endothelium and promotes foam macrophage formation. Those changes promote intimal thickening and promote endothelial dysfunction, then lead to the formation of plaque and atherosclerosis (25). TZDs treatment could attenuate
atherosclerosis lesions partially by improving endothelial function, just as described in an article by Frank et al. (26).

Diabetes is a major risk factor for coronary heart disease (27), and the mortality rate of coronary heart disease is higher in diabetic patients than in non-diabetic subjects (28). Studies have shown that diabetic patients with concomitant coronary atherosclerosis have more extensive and severe coronary artery lesions (29), which may be associated with disorders of glucose metabolism, disorders of lipid metabolism, inflammatory response, and endothelial damage (30–32).

Inflammation and dyslipidemia are strongly associated with the formation of coronary atherosclerosis (33, 34). Adiponectin, an endocrine factor secreted by adipose tissue, plays an important role in insulin resistance, inflammation, and atherosclerosis in diabetes patients (35) (Figure 6). Adiponectin downregulates pro-inflammatory factors such as TNF-α and IL-6 and attenuates atherosclerosis by reducing inflammatory responses, lipid accumulation, and oxidative stress (36).

C reactive protein (CRP) is a sensitive marker of progressive systemic inflammation. And CRP and IL-6 are the most widely studied systemic markers of inflammation in cardiovascular disease. At the same time, adiponectin showed a significant negative correlation with CRP and IL-6 (37). In our study, the meta-analysis showed that serum adiponectin levels were elevated in the TZDs intervention group. It has been proved that TZDs activated the peroxisome proliferator-activated receptor isoforms (PPARγ), which alters the transscription of several genes involved in glycolipid metabolism (38) and thus affects adiponectin levels. On the one hand, clinical and experimental observations suggest that low serum adiponectin levels contribute to ameliorating insulin resistance in obese or overweight patients (39). On the other hand, low adiponectin expression is the cause of diabetic endothelial dysfunction (40).

For indicators of very high heterogeneity, we explored the source of the heterogeneity and removed it to test the stability of the results. It showed that lower levels of CRP and higher levels of TC were observed in the intervention group compared to the control subjects, but they are not entirely reliable (41). TZDs have been reported to affect lipid metabolism. In our study, we found that TZDs affected vessel plaque and adiponectin. And after TZDs treatment, those general inflammation indicators such as CRP and IL-6 only showed a trend of decline, rather than results with significant statistical differences. Unexpectedly, widely used indicators of blood lipids and inflammation, such as IL-6, LDL-C, and HDL-C didn’t exhibit statistical differences. We supposed these results may be due to the quantity and quality of the literature because there is a lot of strong evidence that inflammatory indices are closely related to adiponectin levels. An alternative explanation for blood lipid indicators is that the therapeutic effects of the TZDs maybe not depend on the regulation of lipid metabolism.

Our results suggested that TZDs ameliorated vascular endothelial and plaque-related indices in diabetic patients with atherosclerosis. Besides, our study showed that TZDs didn’t affect serum lipid indicators, indicating that the above effects of TZDs may not depend on the status of serum lipids. Since the endothelium and plaque are very closely related to myocardial infarction, we can then suppose that TZDs may eventually play a protective role in myocardial infarction by raising adiponectin, protecting the endothelium, and delaying plaque development. Recently, in the treatment of diabetes, there have emerged drugs thought to have cardiovascular benefits, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), these drugs exert glucose-lowering effects through novel therapeutic targets, and may play positive roles in coronary atherosclerosis. It has been reported that SGLT2-i treatment accelerated features of plaque stability during atherosclerosis regression (42), and GLP-1RAs alleviated vascular inflammation and plaque burden (43). Both of the drugs have positive effects on the treatment of plaque, then exert potential therapeutic effects on coronary atherosclerosis, which is worth further discussion. Those above provide new ideas for ensuring optimal treatment with few adverse events and unnecessary multiple drugs combination.

Some limitations in our paper: low levels of the literature included; high heterogeneity between studies, and rough integration of rosiglitazone with pioglitazone creates bias. We look forward to more high-quality researches in this field. If the sample size is larger, our conclusion that “TZDs ameliorated the vascular endothelium and plaque in diabetic with atherosclerosis and developed a potential protective effect on myocardial infarction which did not depend on the improvement of lipid profile” may be more reasonable.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

CYX mainly performed the data collection, with assistance from MQZ. QYZ performed the data analysis and interpretation. CYX and LXL drafted the manuscript. WJL provided the critical revisions. All authors contributed to developing the study concept, designing the study, and approved the final version of the manuscript for submission.

Funding

This work was supported by the Decoding Traditional Chinese Medicine, Beijing University of Chinese Medicine project grant (90070161220027).
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this manuscript, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.1043406/full#supplementary-material

References

1. International Diabetes Federation,. Idi Diabetes Atlas, Tenth. Brussels: International Diabetes Federation (2021).

2. Park CS, Han KD, Choi EK, Kim DH, Lee HJ, Lee SR, et al. Lifestyle is associated with atrial fibrillation development in patients with type 2 diabetes mellitus. Sci Rep. (2021) 11:4676. doi: 10.1038/s41598-021-84307-5

3. Yang M, Cheng M, Wang M, Tang Z, Song Z, Cui C, et al. Meta-analysis of the effect of traditional chinese medicine compounds combined with standard western medicine for the treatment of diabetes mellitus complicated by coronary heart disease. Evid Based Complement Alternat Med. (2021) 2021:551542. doi: 10.1155/2021/551542

4. Ku YH, Cho B-J, Kim MJ, Lim S, Park YJ, Jang HC, et al. Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation. BMC Pharmacol Toxicol. (2017) 18:82. doi: 10.1186/s40360-017-0169-y

5. Silverman SL. From randomized controlled trials to observational studies. Am J Med. (2009) 122:114–20. doi: 10.1016/j.amjmed.2008.09.030

6. Wallach J, Wang K, Zhang A, Cheng D, Grosssetta Nardini H, Lin H. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. (2020) 368:l7078. doi: 10.1136/bmj.l7078

7. Zhu J, Yu X, Zheng Y, Li J, Wang Y, Lin Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes Endocrinol. (2020) 8:192–205. doi: 10.1016/S2213-8587(19)30422-9

8. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitivity in type 2 diabetes. Cell Metab. (2014) 20:573–91. doi: 10.1016/j.cmet.2014.08.005

9. Liu Y, Chen X, Li J. Resveratrol protects against oxidized low-density lipoprotein-induced human umbilical vein endothelial cell apoptosis via inhibition of mitochondrial-derived oxidative stress. Mol Med Rep. (2017) 15:2457–64. doi: 10.18223/mmr.2017.6304

10. Page MJ, McKenzie JE, Bossuyt PM, Bouton I, Hoffmann TC, Mulrow CD, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. (2021) 10.1--11.

11. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. (2011) 343:d5928. doi: 10.1136/bmj.d5928

12. Spinelli LM, Pandis N. Fixed-effect versus random-effects model in meta-regression analysis. Am J Oralol Dentofacial Orthop. (2020) 158:770–2. doi: 10.1016/j.amjodo.2020.07.016

13. Bastien M, Poirier P, Brassard P, Arsenault BJ, Bertrand OF, Després J-P, et al. Development of second generation peptides modulating cellular adiponectin receptor responses. Front Physiol. (2014) 2:93. doi: 10.3389/fphys.2014.00093

14. Bertrand OF, Poirier P, Rodès-Cabau J, Rinfret S, Title LM, Dzavik V, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes mellitus: opportunities for intervention. Am J Med. (2007) 120:S26–32. doi: 10.1016/j.amjmed.2007.07.005

15. Ahn C, Kim S, Kim J, Park J, Hong S, Lee K, et al. Pioglitazone Reduces Chemokine Receptor-2 Expressions on CD4+ Cells, Circulating Natural Killer Cells, and Neointima Volume in Type 2 Diabetic Patients. Oxford: Oxford University Press (2016).

16. You SH, Kim BS, Hong SJ, Ahn C-M, Lim D-S. The effects of pioglitazone in reducing atherosclerotic progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasound analysis. Korean Circ J. (2010) 40:625–31. doi: 10.4070/kcj.2010.40.12.625

17. Kitahara H, Kobayashi Y, Iwata Y, Fujimoto Y, Komuro I. Effect of pioglitazone on endothelial dysfunction after sirolimus-eluting stent implantation. Am J Cardiol. (2011) 108:214–9. doi: 10.1016/j.amjcard.2011.03.029

18. Desch S, Sonnenab M, Niebauer J, Sist S, Sareban M, Eitel I, et al. Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes. Diabetes Obesity Metab. (2010) 12:825–8. doi: 10.1111/j.1463-1326.2010.01234.x

19. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care. (2006) 29:1039–45. doi: 10.2373/dij.06-0226

20. Yu J, Zhang Z, Li Z, Feng X, He L, Liu S, et al. Peroxisome proliferator-activated receptor-gamma(Ppargamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res. (2010) 38:86–94. doi: 10.1177/147323001003801110

21. Sha H, Yang L, Liu M, Xia S, Liu Y, Liu F, et al. Adipocyte-spired x-box-binding protein 1 promotes adiponectin multimerization and systemic glucose homeostasis. Diabetes. (2014) 63:867–79. doi: 10.2337/db13-1067

22. Orvos L Jr., Knappe D, Hoffmann R, Kovalsky I, Olah J, Hewitson TD, et al. Development of second generation peptides modulating cellular adiponectin receptor responses. Front Chem. (2014) 2:93. doi: 10.3389/fchem.2014.00093

23. Marzzone T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. Am J Med. (2007) 120:526–32. doi: 10.1016/j.amjmed.2007.07.005

24. Nissen SE, Nicholls SJ, Wolki K, Nesto R, Kupper S, Perez A, et al. Comparison of pioglitazone Vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the periscope randomised controlled trial. Jama. (2008) 299:1561–73. doi: 10.1001/jama.299.13.1561

25. Oudro PK, Fang J, Liu J, Li Y, Li L, Zhao X, et al. Pharmacological management of vascular endothelial dysfunction in diabetes: tcm and western medicine compared based on biomarkers and biochemical parameters. Pharmacol Res. (2020) 158:104893. doi: 10.1016/j.phrs.2020.104893

26. Pustrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. (2004) 27:484–90. doi: 10.2337/diacare.27.2.484

27. Yuan C, Hu J, Parathath S, Grauer L, Casella CB, Bagdasarov S, et al. Human aldose reductase expression prevents atherosclerosis regression in diabetic mice. Diabetes. (2018) 67:1880–91. doi: 10.2337/db18-0156

28. Masuda D, Kobayashi T, Sairou M, Hanada H, Ohama T, Koseki M, et al. Effects of a dipetidyl peptidase 4 inhibitor sitagliptin on glycemic control and lipoprotein metabolism in patients with type 2 diabetes mellitus (Gloria Trial). J Atheroscl Thromb. (2018) 25:512–20. doi: 10.5551/jat.41343
29. Hegde SS, Mallesh P, Yeli S, Gadad VM. Comparative angiographic profile in diabetic and non-diabetic patients with acute coronary syndrome. J Clin Diagn Res. (2014) 8:MC07.

30. Maahs DM, Hokanson JE, Wang H, Kinney GL, Snell-Bergeon JK, East A, et al. Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. Diabetes. (2010) 59:1771–9. doi: 10.2337/db09-1626.

31. Yang L, Chen L, Li D, Xu H, Chen J, Min X, et al. Effect of Glp-1/Glp-1r on the polarization of macrophages in the occurrence and development of atherosclerosis. Mediators Inflamm. (2021) 2021:5568159. doi: 10.1155/2021/5568159.

32. Liu S, Jiang X, Cui X, Wang J, Liu S, Li H, et al. Smooth muscle-specific htr knockout induces defective autophagy and atherosclerosis. Cell Death Dis. (2021) 12:1–14. doi: 10.1038/s41419-021-03671-2.

33. Zhou J, Chen L, Yang X, Huang X, Wang Z, Peng P, et al. Preliminary study of the relationship between promoter methylation of the Angptl2 gene and coronary heart disease. J Clin Lab Anal. (2019) 33:e22702. doi: 10.1002/jcla.22702.

34. Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. (2018) 276:98–108. doi: 10.1016/j.atherosclerosis.2018.07.014.

35. Fang H, Judd R. Adiponectin regulation and function. Compr Physiol. (2018) 8:1031–63. doi: 10.1002/cphy.c170046.

36. Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci. (2020) 21:1219. doi: 10.3390/ijms21041219.

37. Chami HA, Fonseca JD, Vasan RS, Keaney JF Jr., O’Connor GT, Larson MG, et al. Vascular inflammation and sleep disordered breathing: results from the know-Ckd study. Sci Rep. (2020) 10:5598. doi: 10.1038/s41598-020-62465-2.

38. Song SH, Oh TR, Choi HS, Kim CS, Ma SK, Oh KH, et al. High serum adiponectin as a biomarker of renal dysfunction: results from the know-Ckd study. Sci Rep. (2020) 10:5598. doi: 10.1038/s41598-020-62465-2.

39. Pennig J, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Füner L, et al. Plasma levels of high-sensitive c-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques. J Internal Med. (2014) 275:127–33. doi: 10.1111/joim.12133.

40. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease. Cardiovasc Diabetol. (2014) 13:1–10. doi: 10.1186/1475-2840-13-103.

41. Grußmann H, Gonçalves I, Eidsfeldt A, Nituieescu M, Persson A, Nilsson M, et al. Plasma levels of high-sensitive c-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques. J Internal Med. (2014) 275:127–33. doi: 10.1111/joim.12133.

42. Ming C, Scherrer P, Gissler MC, Anto-Michel N, Hoppe N, Füner L, et al. Glucose lowering by Sglt2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic Strz-diabetic mice. Sci Rep. (2019) 9:17937. doi: 10.1038/s41598-019-54224-9.

43. Maisey A, Di L, Ravodina A, Barajas-Espinosa A, Sakamoto A, Chaplin A, et al. Plaque-targeted, proteolysis-resistant, activatable and mri-visible nano-Glp-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis. Theranostics. (2022) 12:2741–57. doi: 10.7150/thno.66456.